Which has higher valuation and earnings, QURE or IMVT?

uniQure has higher revenue and earnings than Immunovant. uniQure is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 192.11 -$198.97M -$3.48 N/A Immunovant N/A N/A -$505.61M -$2.78 N/A

Is QURE or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Immunovant's return on equity of -65.66% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,154.42% -145.81% -27.15% Immunovant N/A -65.66% -59.88%

Does the media favor QURE or IMVT?

In the previous week, uniQure had 60 more articles in the media than Immunovant. MarketBeat recorded 62 mentions for uniQure and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat uniQure's score of 0.52 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is QURE or LEGN more profitable?

Legend Biotech has a net margin of -21.98% compared to uniQure's net margin of -1,154.42%. Legend Biotech's return on equity of -24.92% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,154.42% -145.81% -27.15% Legend Biotech -21.98% -24.92% -14.87%

Does the media prefer QURE or LEGN?

In the previous week, uniQure had 56 more articles in the media than Legend Biotech. MarketBeat recorded 62 mentions for uniQure and 6 mentions for Legend Biotech. uniQure's average media sentiment score of 0.52 beat Legend Biotech's score of 0.18 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, PTCT or QURE?

PTC Therapeutics has higher revenue and earnings than uniQure. PTC Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PTC Therapeutics $1.73B 3.94 $682.64M -$2.33 N/A uniQure $16.10M 192.11 -$198.97M -$3.48 N/A

Is PTCT or QURE more profitable?

PTC Therapeutics has a net margin of -22.58% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% uniQure -1,154.42% -145.81% -27.15%

Does the media refer more to PTCT or QURE?

In the previous week, uniQure had 49 more articles in the media than PTC Therapeutics. MarketBeat recorded 62 mentions for uniQure and 13 mentions for PTC Therapeutics. uniQure's average media sentiment score of 0.52 beat PTC Therapeutics' score of 0.49 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MIRM or QURE?

Mirum Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mirum Pharmaceuticals $521.31M 13.01 -$23.36M -$13.61 N/A uniQure $16.10M 192.11 -$198.97M -$3.48 N/A

Does the media refer more to MIRM or QURE?

In the previous week, uniQure had 54 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 8 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat uniQure's score of 0.52 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor QURE or RYTM?

In the previous week, uniQure had 58 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat uniQure's score of 0.52 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

uniQure (QURE) Competitors

$49.04 +4.65 (+10.48%)

Closing price 04:00 PM Eastern

Extended Trading

$48.72 -0.31 (-0.64%)

As of 07:55 PM Eastern

Compare

QURE vs. IMVT, LEGN, PTCT, MIRM, and RYTM

Should you buy uniQure stock or one of its competitors? MarketBeat compares uniQure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with uniQure include Immunovant (IMVT), Legend Biotech (LEGN), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does uniQure compare to Immunovant?

uniQure (NASDAQ:QURE) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Immunovant has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Immunovant's return on equity of -65.66% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Immunovant	N/A	-65.66%	-59.88%

78.8% of uniQure shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

uniQure presently has a consensus price target of $58.92, indicating a potential upside of 20.14%. Immunovant has a consensus price target of $37.33, indicating a potential downside of 0.76%. Given uniQure's stronger consensus rating and higher possible upside, analysts clearly believe uniQure is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, uniQure had 60 more articles in the media than Immunovant. MarketBeat recorded 62 mentions for uniQure and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat uniQure's score of 0.52 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has higher revenue and earnings than Immunovant. uniQure is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

uniQure has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Summary

uniQure beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does uniQure compare to Legend Biotech?

uniQure (NASDAQ:QURE) and Legend Biotech (NASDAQ:LEGN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

In the previous week, uniQure had 56 more articles in the media than Legend Biotech. MarketBeat recorded 62 mentions for uniQure and 6 mentions for Legend Biotech. uniQure's average media sentiment score of 0.52 beat Legend Biotech's score of 0.18 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

uniQure has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A
Legend Biotech	$1.14B	4.78	-$296.80M	-$0.68	N/A

uniQure presently has a consensus price target of $58.92, suggesting a potential upside of 20.14%. Legend Biotech has a consensus price target of $60.23, suggesting a potential upside of 105.57%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Legend Biotech has a net margin of -21.98% compared to uniQure's net margin of -1,154.42%. Legend Biotech's return on equity of -24.92% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Legend Biotech	-21.98%	-24.92%	-14.87%

78.8% of uniQure shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

uniQure has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

uniQure beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does uniQure compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and uniQure (NASDAQ:QURE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

PTC Therapeutics has a net margin of -22.58% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
uniQure	-1,154.42%	-145.81%	-27.15%

78.8% of uniQure shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

PTC Therapeutics currently has a consensus price target of $91.36, indicating a potential upside of 11.23%. uniQure has a consensus price target of $58.92, indicating a potential upside of 20.14%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

In the previous week, uniQure had 49 more articles in the media than PTC Therapeutics. MarketBeat recorded 62 mentions for uniQure and 13 mentions for PTC Therapeutics. uniQure's average media sentiment score of 0.52 beat PTC Therapeutics' score of 0.49 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has higher revenue and earnings than uniQure. PTC Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.94	$682.64M	-$2.33	N/A
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A

PTC Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Summary

uniQure beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does uniQure compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and uniQure (NASDAQ:QURE) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

78.8% of uniQure shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, uniQure had 54 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 8 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat uniQure's score of 0.52 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.01	-$23.36M	-$13.61	N/A
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A

Mirum Pharmaceuticals has a net margin of -140.24% compared to uniQure's net margin of -1,154.42%. Mirum Pharmaceuticals' return on equity of -11.28% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
uniQure	-1,154.42%	-145.81%	-27.15%

Mirum Pharmaceuticals presently has a consensus target price of $139.80, indicating a potential upside of 25.73%. uniQure has a consensus target price of $58.92, indicating a potential upside of 20.14%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Mirum Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats uniQure on 12 of the 17 factors compared between the two stocks.

How does uniQure compare to Rhythm Pharmaceuticals?

uniQure (NASDAQ:QURE) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, uniQure had 58 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat uniQure's score of 0.52 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

uniQure has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

uniQure presently has a consensus price target of $58.92, indicating a potential upside of 20.14%. Rhythm Pharmaceuticals has a consensus price target of $133.13, indicating a potential upside of 25.36%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Rhythm Pharmaceuticals has higher revenue and earnings than uniQure. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A
Rhythm Pharmaceuticals	$189.76M	38.35	-$196.54M	-$3.13	N/A

Summary

Rhythm Pharmaceuticals beats uniQure on 11 of the 17 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.80B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-14.09	19.75	24.92	23.98
Price / Sales	192.11	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	15.37	8.29	10.79	6.50
Net Income	-$198.97M	$23.85M	$3.56B	$336.88M
7 Day Performance	81.70%	5.21%	1.67%	-0.22%
1 Month Performance	102.73%	2.19%	0.43%	0.77%
1 Year Performance	251.54%	60.99%	32.84%	31.57%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	2.6904 of 5 stars	$49.04 +10.5%	$58.92 +20.1%	+212.4%	$2.80B	$16.10M	N/A	500	Trending News Insider Trade
IMVT Immunovant	1.7671 of 5 stars	$33.62 +2.3%	$37.33 +11.0%	+141.1%	$6.75B	N/A	N/A	120
LEGN Legend Biotech	4.4006 of 5 stars	$35.87 -1.1%	$60.23 +67.9%	-13.7%	$6.74B	$1.03B	N/A	2,965
PTCT PTC Therapeutics	2.508 of 5 stars	$75.14 +0.6%	$91.36 +21.6%	+61.3%	$6.20B	$1.73B	N/A	1,410	News Coverage Insider Trade
MIRM Mirum Pharmaceuticals	4.1272 of 5 stars	$99.35 -0.2%	$138.36 +39.3%	+114.1%	$6.07B	$521.31M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. IMVT, LEGN, PTCT, MIRM, and RYTM

How does uniQure compare to Immunovant?

Summary

How does uniQure compare to Legend Biotech?

Summary

How does uniQure compare to PTC Therapeutics?

Summary

How does uniQure compare to Mirum Pharmaceuticals?

Summary

How does uniQure compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. IMVT, LEGN, PTCT, MIRM, and RYTM

How does uniQure compare to Immunovant?

Is QURE or IMVT more profitable?

Do institutionals and insiders hold more shares of QURE or IMVT?

Do analysts recommend QURE or IMVT?

Does the media favor QURE or IMVT?

Which has higher valuation and earnings, QURE or IMVT?

Which has more risk and volatility, QURE or IMVT?

Summary

How does uniQure compare to Legend Biotech?

Does the media prefer QURE or LEGN?

Which has preferable valuation & earnings, QURE or LEGN?

Do analysts prefer QURE or LEGN?

Is QURE or LEGN more profitable?

Do insiders & institutionals hold more shares of QURE or LEGN?

Which has more risk & volatility, QURE or LEGN?

Summary

How does uniQure compare to PTC Therapeutics?

Is PTCT or QURE more profitable?

Do insiders & institutionals have more ownership in PTCT or QURE?

Do analysts prefer PTCT or QURE?

Does the media refer more to PTCT or QURE?

Which has better earnings & valuation, PTCT or QURE?

Which has more volatility & risk, PTCT or QURE?

Summary

How does uniQure compare to Mirum Pharmaceuticals?

Do insiders and institutionals hold more shares of MIRM or QURE?

Does the media refer more to MIRM or QURE?

Which has higher valuation & earnings, MIRM or QURE?

Is MIRM or QURE more profitable?

Do analysts prefer MIRM or QURE?

Which has more risk and volatility, MIRM or QURE?

Summary

How does uniQure compare to Rhythm Pharmaceuticals?

Does the media favor QURE or RYTM?

Do insiders & institutionals have more ownership in QURE or RYTM?

Is QURE or RYTM more profitable?

Which has more risk & volatility, QURE or RYTM?

Do analysts prefer QURE or RYTM?

Which has higher earnings and valuation, QURE or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools